Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

← catalyst calendar

NCT07019909

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
400actual
Sites
3
Country
China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-07-06actualWhen the study began enrolling
Primary completion2026-01-28actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-01-28actualThe whole study's end, after follow-up
First posted2025-06-13actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-02-25actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Pneumococcal Disease

Interventions

  • Biological: 20vPnC
  • Biological: 13vPnC

Primary outcomes

what the primary-completion date above is the date OF
Percentage of participants reporting prompted local reactions within 7 days following investigational product administration
measured Within 7 days after vaccination
Percentage of participants reporting prompted systemic events within 7 days following investigational product administration
measured Within 7 days after vaccination
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
measured Within 1 month after vaccination
Percentage of participants reporting serious adverse events (SAEs) throughout the study
measured Within 6 months after vaccination
Percentage of participants reporting abnormal hematology, biochemistry, and urinalysis and microscopy laboratory values
measured 3 to 5 days after vaccination

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed